SG11202110958QA - Anti-vegf protein compositions and methods for producing the same - Google Patents
Anti-vegf protein compositions and methods for producing the sameInfo
- Publication number
- SG11202110958QA SG11202110958QA SG11202110958QA SG11202110958QA SG11202110958QA SG 11202110958Q A SG11202110958Q A SG 11202110958QA SG 11202110958Q A SG11202110958Q A SG 11202110958QA SG 11202110958Q A SG11202110958Q A SG 11202110958QA SG 11202110958Q A SG11202110958Q A SG 11202110958QA
- Authority
- SG
- Singapore
- Prior art keywords
- producing
- methods
- same
- protein compositions
- vegf protein
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
- C12N5/0031—Serum-free culture media
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21004—Trypsin (3.4.21.4)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/80—Fraction collectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2529/00—Culture process characterised by the use of electromagnetic stimulation
- C12N2529/10—Stimulation by light
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N2030/022—Column chromatography characterised by the kind of separation mechanism
- G01N2030/027—Liquid chromatography
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Vascular Medicine (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962944635P | 2019-12-06 | 2019-12-06 | |
US202063065012P | 2020-08-13 | 2020-08-13 | |
PCT/US2020/046823 WO2021112924A1 (en) | 2019-12-06 | 2020-08-18 | Anti-vegf protein compositions and methods for producing the same |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202110958QA true SG11202110958QA (en) | 2021-10-28 |
Family
ID=76210828
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202110955VA SG11202110955VA (en) | 2019-12-06 | 2020-08-18 | Anti-vegf protein compositions and methods for producing the same |
SG11202110972UA SG11202110972UA (en) | 2019-12-06 | 2020-08-18 | Anti-vegf protein compositions and methods for producing the same |
SG11202110953UA SG11202110953UA (en) | 2019-12-06 | 2020-08-18 | Anti-vegf protein compositions and methods for producing the same |
SG11202110958QA SG11202110958QA (en) | 2019-12-06 | 2020-08-18 | Anti-vegf protein compositions and methods for producing the same |
SG11202110968VA SG11202110968VA (en) | 2019-12-06 | 2020-08-18 | Anti-vegf protein compositions and methods for producing the same |
SG11202110964QA SG11202110964QA (en) | 2019-12-06 | 2020-08-18 | Anti-vegf protein compositions and methods for producing the same |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202110955VA SG11202110955VA (en) | 2019-12-06 | 2020-08-18 | Anti-vegf protein compositions and methods for producing the same |
SG11202110972UA SG11202110972UA (en) | 2019-12-06 | 2020-08-18 | Anti-vegf protein compositions and methods for producing the same |
SG11202110953UA SG11202110953UA (en) | 2019-12-06 | 2020-08-18 | Anti-vegf protein compositions and methods for producing the same |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202110968VA SG11202110968VA (en) | 2019-12-06 | 2020-08-18 | Anti-vegf protein compositions and methods for producing the same |
SG11202110964QA SG11202110964QA (en) | 2019-12-06 | 2020-08-18 | Anti-vegf protein compositions and methods for producing the same |
Country Status (18)
Country | Link |
---|---|
US (33) | US11186625B2 (en) |
EP (6) | EP3906249A1 (en) |
JP (12) | JP2022547652A (en) |
KR (12) | KR20230051297A (en) |
CN (6) | CN114206925A (en) |
AU (12) | AU2020398125C1 (en) |
BR (5) | BR112021025432A2 (en) |
CA (4) | CA3129193C (en) |
CO (6) | CO2021018214A2 (en) |
IL (16) | IL288360B2 (en) |
MX (10) | MX2022006788A (en) |
MY (12) | MY193349A (en) |
NZ (6) | NZ781136A (en) |
PE (6) | PE20221770A1 (en) |
SG (6) | SG11202110955VA (en) |
TW (6) | TW202122417A (en) |
WO (7) | WO2021112926A1 (en) |
ZA (3) | ZA202107646B (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY193349A (en) * | 2019-12-06 | 2022-10-06 | Regeneron Pharma | Anti-vegf protein compositions and methods for producing the same |
WO2022234412A1 (en) | 2021-05-03 | 2022-11-10 | Lupin Limited | A process for purification of fc-fusion proteins |
US20230077710A1 (en) * | 2021-09-08 | 2023-03-16 | Regeneron Pharmaceuticals, Inc. | HIGH-THROUGHPUT AND MASS-SPECTROMETRY-BASED METHOD FOR QUANTITATING ANTIBODIES AND OTHER Fc-CONTAINING PROTEINS |
CN116162148A (en) * | 2021-11-24 | 2023-05-26 | 苏州光度生物科技有限公司 | Multispecific ligand binding molecules and uses thereof |
WO2023137143A1 (en) * | 2022-01-14 | 2023-07-20 | Shattuck Labs, Inc. | Methods of contaminant removal from protein isolates |
WO2023230486A2 (en) * | 2022-05-23 | 2023-11-30 | Inhalon Biopharma, Inc. | Compositions and methods for inhalable therapeutics |
WO2024114799A1 (en) * | 2022-12-01 | 2024-06-06 | 信达生物制药(苏州)有限公司 | Trispecific fusion protein and use thereof |
US20240229002A1 (en) * | 2023-01-06 | 2024-07-11 | Seismic Therapeutic, Inc. | Protease variants and uses thereof |
KR20240115650A (en) | 2023-01-19 | 2024-07-26 | 주식회사 스카이테라퓨틱스 | An amorphous nano molecule of tyrosine kinase inhibitors and containing composition and method for producing the same |
Family Cites Families (132)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1522343A (en) | 1923-05-02 | 1925-01-06 | Thom Clarence | Magnetic separator |
US4534972A (en) | 1983-03-29 | 1985-08-13 | Miles Laboratories, Inc. | Protein compositions substantially free from infectious agents |
DE3871206D1 (en) | 1987-03-24 | 1992-06-25 | Grace W R & Co | BASIC MEDIUM FOR A CELL CULTURE. |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
GB9022545D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Culture medium |
US20030108545A1 (en) | 1994-02-10 | 2003-06-12 | Patricia Rockwell | Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist |
AU3374795A (en) * | 1994-08-29 | 1996-03-22 | Prizm Pharmaceuticals, Inc. | Conjugates of vascular endothelial growth factor with targeted agents |
US5705364A (en) | 1995-06-06 | 1998-01-06 | Genentech, Inc. | Mammalian cell culture process |
US5721121A (en) | 1995-06-06 | 1998-02-24 | Genentech, Inc. | Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein |
US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
EP2221361A3 (en) | 1996-08-30 | 2011-02-09 | Life Technologies Corporation | Method for producing a polypeptide in vitro in mammalian cells in a protein-free and serum-free culture medium |
US5804420A (en) | 1997-04-18 | 1998-09-08 | Bayer Corporation | Preparation of recombinant Factor VIII in a protein free medium |
US6475725B1 (en) | 1997-06-20 | 2002-11-05 | Baxter Aktiengesellschaft | Recombinant cell clones having increased stability and methods of making and using the same |
SE519827C2 (en) | 1998-03-30 | 2003-04-15 | Viranative Ab | Nutritional medium containing methionine and its use |
US7306799B2 (en) | 1999-06-08 | 2007-12-11 | Regeneron Pharmaceuticals, Inc. | Use of VEGF inhibitors for treatment of eye disorders |
US7396664B2 (en) | 1999-06-08 | 2008-07-08 | Regeneron Pharmaceuticals, Inc. | VEGF-binding fusion proteins and nucleic acids encoding the same |
US6833349B2 (en) | 1999-06-08 | 2004-12-21 | Regeneron Pharmaceuticals, Inc. | Methods of treating inflammatory skin diseases |
US7303746B2 (en) | 1999-06-08 | 2007-12-04 | Regeneron Pharmaceuticals, Inc. | Methods of treating eye disorders with modified chimeric polypeptides |
BRPI0011407B8 (en) * | 1999-06-08 | 2021-05-25 | Regeneron Pharma | chimeric nucleic acid molecule, fusion polypeptide, expression vector, host vector system, and methods of producing a fusion polypeptide |
US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
WO2001039793A2 (en) * | 1999-11-30 | 2001-06-07 | Smithkline Beecham P.L.C. | Pharmaceutical compositions containing sema7a polypeptides |
IL152315A (en) | 2000-05-26 | 2010-04-15 | Bristol Myers Squibb Co | Soluble ctla4 mutant molecules and pharmaceutical compositions containing the same |
EP1360314B1 (en) | 2001-02-15 | 2009-01-14 | Centocor, Inc. | Chemically defined medium for cultured mammalian cells |
IL158328A0 (en) | 2001-04-13 | 2004-05-12 | Wyeth Corp | Surface proteins of streptococcus pyogenes |
WO2002101019A2 (en) | 2001-06-13 | 2002-12-19 | Genentech, Inc. | Methods of culturing animal cells and polypeptide production in animal cells |
GB0130228D0 (en) | 2001-12-18 | 2002-02-06 | Hansa Medica Ab | Protein |
US8777906B1 (en) | 2002-01-24 | 2014-07-15 | Robin Scott Gray | Syringe with inspection window |
US7332303B2 (en) | 2002-12-23 | 2008-02-19 | Bristol-Myers Squibb Company | Product quality enhancement in mammalian cell culture processes for protein production |
US7399612B2 (en) | 2003-06-30 | 2008-07-15 | Regeneron Pharmaceuticals, Inc. | VEGF-binding fusion proteins and nucleic acids encoding the same |
CN100537751C (en) | 2004-05-12 | 2009-09-09 | 华东理工大学 | The serum free medium that a kind of suitable Chinese hamster ovary cell is cultivated |
TWI374935B (en) | 2004-08-27 | 2012-10-21 | Pfizer Ireland Pharmaceuticals | Production of α-abeta |
US20060094104A1 (en) | 2004-10-29 | 2006-05-04 | Leopold Grillberger | Animal protein-free media for cultivation of cells |
AU2005302516A1 (en) * | 2004-10-29 | 2006-05-11 | Centocor, Inc. | Chemically defined media compositions |
EP1877438A2 (en) | 2005-02-02 | 2008-01-16 | Regeneron Pharmaceuticals, Inc. | Method of treating eye injury with local administration of a vegf inhibitor |
EP3195874A1 (en) | 2005-03-25 | 2017-07-26 | Regeneron Pharmaceuticals, Inc. | Vegf antagonist formulations |
GB0511769D0 (en) * | 2005-06-09 | 2005-07-20 | Hansa Medical Ab | Treatment |
AU2006256891B2 (en) * | 2005-06-09 | 2011-08-04 | Hansa Biopharma AB | Use of the ideS proteinase (from s. pyogenes) for treating autoimmune diseases and graft rejection |
CN1778903A (en) | 2005-09-29 | 2006-05-31 | 华东理工大学 | High-density continous pouring culture of animal cell |
EP2522717B1 (en) | 2006-01-04 | 2014-04-02 | Baxter International Inc | Oligopeptide-free cell culture media |
CN100502945C (en) | 2006-03-31 | 2009-06-24 | 成都康弘生物科技有限公司 | Application of fusion protein of VEGF receptor for treating disease of eye |
EP2364691B1 (en) | 2006-06-16 | 2013-04-24 | Regeneron Pharmaceuticals, Inc. | VEGF antagonist formulations suitable for intravitreal administration |
PT2495307T (en) | 2006-07-13 | 2018-05-10 | Wyeth Llc | Production of coagulation factor ix with improved glycosylation pattern |
CN101541825B (en) * | 2006-08-28 | 2013-08-14 | 阿雷斯贸易股份有限公司 | Process for the purification of Fc-fusion proteins |
NZ575974A (en) | 2006-09-10 | 2012-03-30 | Glycotope Gmbh | Use of human cells of myeloid leukaemia origin for expression of antibodies |
SG10201510384UA (en) | 2006-09-13 | 2016-01-28 | Abbvie Inc | Cell culture improvements |
US10259860B2 (en) | 2007-02-27 | 2019-04-16 | Aprogen Inc. | Fusion proteins binding to VEGF and angiopoietin |
PT2137655E (en) | 2007-04-16 | 2012-09-14 | Momenta Pharmaceuticals Inc | Defined glycoprotein products and related methods |
WO2008154014A2 (en) | 2007-06-11 | 2008-12-18 | Amgen Inc. | A method for culturing mammalian cells to improve recombinant protein production |
US20110117601A1 (en) | 2007-08-31 | 2011-05-19 | Markus Haberger | Glycosylation Profile Analysis |
EP2225273B1 (en) * | 2007-12-21 | 2012-05-23 | Roche Glycart AG | Stability testing of antibodies |
KR101415099B1 (en) | 2008-07-31 | 2014-07-08 | 고쿠리츠 다이가쿠 호진 교토 다이가쿠 | Molding material containing unsaturated polyester resin and microfibrillated plant fiber |
EP2342318A1 (en) | 2008-09-26 | 2011-07-13 | Schering Corporation | High titer antibody production |
EP2435577A4 (en) | 2009-05-26 | 2016-04-13 | Momenta Pharmaceuticals Inc | Production of glycoproteins |
MX342623B (en) | 2009-06-26 | 2016-10-06 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format. |
PT2459702T (en) | 2009-07-31 | 2016-08-02 | Baxalta Inc | Cell culture medium for adamts protein expression |
WO2011050071A2 (en) * | 2009-10-20 | 2011-04-28 | Abbott Laboratories | Isolation and purification of anti-il-13 antibodies using protein a affinity chromatography |
EP2325296A1 (en) | 2009-11-20 | 2011-05-25 | LEK Pharmaceuticals d.d. | Production of glycoproteins with low N-glycolylneuraminic acid (Neu5Gc) content |
US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
WO2012097019A1 (en) | 2011-01-13 | 2012-07-19 | Regeneron Pharmaceuticals, Inc. | Use of a vegf antagonist to treat angiogenic eye disorders |
CN102653729B (en) | 2011-03-04 | 2014-07-16 | 上海赛金生物医药有限公司 | Culture medium used for Chinese hamster ovary cells |
WO2012140487A1 (en) | 2011-04-11 | 2012-10-18 | Cellcura Asa | Protein-free culture media products for manufacturing viral-based vaccines |
CN104024423B (en) | 2011-04-29 | 2017-03-15 | 拜康研究有限公司 | For reducing the method and the method for producing its antibody of antibody heterogeneity |
MY166973A (en) | 2011-04-29 | 2018-07-27 | Biocon Res Limited | Methods for reducing accumulation of lactate during culturing and method for producing polypeptide |
CA2777978A1 (en) | 2011-05-27 | 2012-11-27 | Abbott Biotherapeutics Corp. | Dac hyp compositions and methods |
WO2013028330A2 (en) | 2011-08-19 | 2013-02-28 | Emd Millipore Corporation | Methods of reducing level of one of more impurities in a sample during protein purification |
WO2013054250A1 (en) * | 2011-10-10 | 2013-04-18 | Dr Reddy's Laboratories Limited | Purification method |
EP3578203A1 (en) * | 2011-10-28 | 2019-12-11 | Integritybio Inc. | Protein formulations containing amino acids |
US20130281355A1 (en) | 2012-04-24 | 2013-10-24 | Genentech, Inc. | Cell culture compositions and methods for polypeptide production |
CN102757496B (en) * | 2012-06-07 | 2014-06-18 | 山东泉港药业有限公司 | Method for purifying and preparing anti-VEGF antibody fragment |
DE202012011016U1 (en) * | 2012-07-03 | 2012-11-28 | Novartis Ag | Aflibercept syringe |
WO2014015098A1 (en) * | 2012-07-18 | 2014-01-23 | Siemens Healthcare Diagnostics Inc. | A method of normalizing biological samples |
SG11201500480TA (en) * | 2012-08-02 | 2015-02-27 | Sanofi Sa | Article of manufacture comprising aflibercept or ziv-aflibercept |
US9206390B2 (en) | 2012-09-02 | 2015-12-08 | Abbvie, Inc. | Methods to control protein heterogeneity |
JOP20200236A1 (en) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof |
EP2722673B1 (en) * | 2012-10-17 | 2017-07-12 | Hexal AG | Improved method of mapping glycans of glycoproteins |
US20140271622A1 (en) | 2013-03-14 | 2014-09-18 | Momenta Pharmaceuticals, Inc. | Methods of cell culture |
US9217168B2 (en) | 2013-03-14 | 2015-12-22 | Momenta Pharmaceuticals, Inc. | Methods of cell culture |
US8956830B2 (en) | 2013-03-14 | 2015-02-17 | Momenta Pharmaceuticals, Inc. | Methods of cell culture |
CN103146648A (en) | 2013-03-14 | 2013-06-12 | 北京京蒙高科干细胞技术有限公司 | Animal source-free and serum-free culture medium of lymphocyte |
CA2906175C (en) * | 2013-03-15 | 2022-12-13 | Daniel J. Capon | Hybrid immunoglobulin containing non-peptidyl linkage |
AR095196A1 (en) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | SERUM FREE CELL CULTIVATION MEDIA |
ES2798307T3 (en) | 2013-03-15 | 2020-12-10 | Hoffmann La Roche | Antioxidant Cell Culture Compositions and Procedures for Polypeptide Production |
CN103773732B (en) | 2013-06-08 | 2016-05-11 | 李锋 | The production technology of definite culture medium, its application and the large-scale culture mammalian cell of a kind of chemical composition |
US10154971B2 (en) | 2013-06-17 | 2018-12-18 | Adamas Pharma, Llc | Methods of administering amantadine |
US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
WO2015058369A1 (en) | 2013-10-23 | 2015-04-30 | Sanofi (China) Investment Co., Ltd. | Use of aflibercept and docetaxel for the treatment of nasopharyngeal carcinoma |
EP3102589A1 (en) | 2014-02-04 | 2016-12-14 | Biogen MA Inc. | Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications |
CN104073464A (en) | 2014-07-08 | 2014-10-01 | 西藏天虹科技股份有限责任公司 | Serum-free CHO cell culture medium and preparation method thereof |
AR101262A1 (en) | 2014-07-26 | 2016-12-07 | Regeneron Pharma | PURIFICATION PLATFORM FOR Bispecific Antibodies |
GB201502305D0 (en) * | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
GB201502306D0 (en) * | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
ES2839211T3 (en) * | 2015-03-12 | 2021-07-05 | Medimmune Llc | Method for Purifying Albumin Fusion Proteins |
KR101867134B1 (en) * | 2015-03-23 | 2018-06-12 | 한양대학교 산학협력단 | Cell culture media for production of target material with high yield using mammalian cell, method for culturing cells and production of target material using the cell culture media |
CA2996643A1 (en) | 2015-04-01 | 2016-10-06 | Boehringer Ingelheim International Gmbh | Cell culture medium |
CN105002242A (en) | 2015-07-23 | 2015-10-28 | 苏州康聚生物科技有限公司 | Serum-free culture medium for efficiently expressing recombinant human thyroid-stimulating hormone in CHO cells and application thereof |
TW202340452A (en) | 2015-08-04 | 2023-10-16 | 美商再生元醫藥公司 | Taurine supplemented cell culture medium and methods of use |
WO2017025928A2 (en) | 2015-08-12 | 2017-02-16 | Novartis Ag | Methods of treating ophthalmic disorders |
US11208441B2 (en) * | 2015-10-22 | 2021-12-28 | Protenova Co., Ltd. | Immunoglobulin-binding polypeptide |
EP3377100A1 (en) * | 2015-11-18 | 2018-09-26 | Formycon AG | Pre-filled pharmaceutical package comprising a liquid formulation of a vegf-antagonist |
JP2019501687A (en) | 2015-11-18 | 2019-01-24 | フォーマイコン アーゲーFormycon Ag | Prefilled plastic syringe containing VEGF antagonist |
CN105368808B (en) * | 2015-11-30 | 2019-04-30 | 苏州康聚生物科技有限公司 | A kind of IdeS protease, preparation method and application |
FI3394103T3 (en) | 2015-12-22 | 2023-08-30 | Regeneron Pharma | Combination of anti-pd-1 antibodies and bispecific anti-cd20/anti-cd3 antibodies to treat cancer |
WO2017112762A1 (en) | 2015-12-22 | 2017-06-29 | Regeneron Pharmaceuticals, Inc. | Bispecific anti-cd20/anti-cd3 antibodies to treat acute lymphoblastic leukemia |
EP3196646B1 (en) * | 2016-01-19 | 2019-12-18 | Hexal AG | Methods of mapping protein variants |
EP3407868A1 (en) | 2016-01-26 | 2018-12-05 | Formycon AG | Liquid formulation of a vegf antagonist |
WO2017168296A1 (en) * | 2016-03-29 | 2017-10-05 | Navya Biologicals Pvt. Ltd | A process for purification of fc-fusion proteins |
KR101685532B1 (en) * | 2016-04-26 | 2016-12-13 | 한국프라임제약주식회사 | A VEGFR fusion protein |
CN106279412A (en) * | 2016-09-12 | 2017-01-04 | 广东东阳光药业有限公司 | A kind of purification process of anti-vegf class monoclonal antibody |
RS64691B1 (en) | 2016-09-23 | 2023-11-30 | Regeneron Pharma | Bi specific anti-muc16-cd3 antibodies and anti-muc16 drug conjugates |
MX2019003325A (en) | 2016-09-23 | 2019-08-05 | Regeneron Pharma | Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof. |
TWI782930B (en) | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | Anti-met antibodies, bispecific antigen binding molecules that bind met, and methods of use thereof |
JP7116059B2 (en) * | 2016-11-21 | 2022-08-09 | ジャスト-エヴォテック バイオロジックス、インコーポレイテッド | Aflibercept preparations and their use |
GEP20237513B (en) * | 2016-12-23 | 2023-06-12 | Serum Institute Of India Pvt Ltd | Improved methods for enhancing antibody productivity in mammalian cell culture and minimizing aggregation during downstream, formulation processes and stable antibody formulations obtained thereof |
US11266745B2 (en) | 2017-02-08 | 2022-03-08 | Imaginab, Inc. | Extension sequences for diabodies |
US10941178B2 (en) * | 2017-03-17 | 2021-03-09 | Gilead Sciences, Inc. | Method of purifying an antibody |
KR101861163B1 (en) | 2017-04-26 | 2018-05-25 | 삼천당제약주식회사 | Ophthalmic pharmaceutical composition |
US20210228738A1 (en) * | 2017-07-17 | 2021-07-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins |
JP7097433B2 (en) * | 2017-08-17 | 2022-07-07 | ジャスト-エヴォテック バイオロジックス、インコーポレイテッド | How to purify glycosylated proteins from host cell galectin and other contaminants |
MX2020003945A (en) * | 2017-10-18 | 2020-11-09 | Regenxbio Inc | Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified vegf-trap. |
CN111356471A (en) * | 2017-11-20 | 2020-06-30 | 济世发展生物药业有限公司 | Abutip formulation comprising lysine salt as tonicity modifier and use thereof |
CN109929027B (en) * | 2017-12-15 | 2020-10-09 | 山东博安生物技术有限公司 | Method for purifying recombinant fusion protein by linear elution step |
CN109929038B (en) * | 2017-12-15 | 2020-10-09 | 山东博安生物技术有限公司 | Purification method of VEGF (vascular endothelial growth factor) capture agent fusion protein |
EP3761953A1 (en) * | 2018-03-08 | 2021-01-13 | Coherus Biosciences, Inc. | Stable aqueous formulations of aflibercept |
US11426446B2 (en) | 2018-03-08 | 2022-08-30 | Coherus Biosciences, Inc. | Stable aqueous formulations of aflibercept |
CA3093699A1 (en) | 2018-03-13 | 2019-09-19 | Amgen Inc. | Methods for the preparation of trypsin-resistant polypeptides for mass spectrometric analysis |
EP3790532A1 (en) | 2018-05-10 | 2021-03-17 | Regeneron Pharmaceuticals, Inc. | High concentration vegf receptor fusion protein containing formulations |
WO2020102740A2 (en) * | 2018-11-16 | 2020-05-22 | Spark Therapeutics, Inc. | Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins |
JP2022523063A (en) * | 2019-01-30 | 2022-04-21 | アムジエン・インコーポレーテツド | Aflibercept attributes and their characterization and modification methods |
EP3969564A1 (en) | 2019-05-16 | 2022-03-23 | Formycon AG | Method for reducing methionine oxidation in recombinant proteins |
KR102286892B1 (en) * | 2019-07-08 | 2021-08-06 | 삼천당제약주식회사 | Refining method of ophthalmic protein pharmaceuticals |
MY193349A (en) * | 2019-12-06 | 2022-10-06 | Regeneron Pharma | Anti-vegf protein compositions and methods for producing the same |
-
2020
- 2020-08-18 MY MYPI2022002191A patent/MY193349A/en unknown
- 2020-08-18 NZ NZ781136A patent/NZ781136A/en unknown
- 2020-08-18 US US16/996,293 patent/US11186625B2/en active Active
- 2020-08-18 BR BR112021025432A patent/BR112021025432A2/en active Search and Examination
- 2020-08-18 AU AU2020398125A patent/AU2020398125C1/en active Active
- 2020-08-18 KR KR1020237010912A patent/KR20230051297A/en active Application Filing
- 2020-08-18 CN CN202080055633.6A patent/CN114206925A/en active Pending
- 2020-08-18 PE PE2022001020A patent/PE20221770A1/en unknown
- 2020-08-18 SG SG11202110955VA patent/SG11202110955VA/en unknown
- 2020-08-18 SG SG11202110972UA patent/SG11202110972UA/en unknown
- 2020-08-18 US US16/996,030 patent/US11104715B2/en active Active
- 2020-08-18 WO PCT/US2020/046834 patent/WO2021112926A1/en active Application Filing
- 2020-08-18 CN CN202080058870.8A patent/CN114401994A/en active Pending
- 2020-08-18 IL IL288360A patent/IL288360B2/en unknown
- 2020-08-18 KR KR1020227002040A patent/KR20220038062A/en not_active IP Right Cessation
- 2020-08-18 SG SG11202110953UA patent/SG11202110953UA/en unknown
- 2020-08-18 EP EP20764873.4A patent/EP3906249A1/en active Pending
- 2020-08-18 IL IL288351A patent/IL288351B2/en unknown
- 2020-08-18 CN CN202080055314.5A patent/CN114423783A/en active Pending
- 2020-08-18 PE PE2022001023A patent/PE20221789A1/en unknown
- 2020-08-18 IL IL302538A patent/IL302538A/en unknown
- 2020-08-18 EP EP20765397.3A patent/EP3906302A1/en active Pending
- 2020-08-18 MY MYPI2021006216A patent/MY190626A/en unknown
- 2020-08-18 IL IL288357A patent/IL288357B2/en unknown
- 2020-08-18 MY MYPI2021006235A patent/MY190627A/en unknown
- 2020-08-18 MY MYPI2021006226A patent/MY190686A/en unknown
- 2020-08-18 WO PCT/US2020/046862 patent/WO2021112929A1/en active Application Filing
- 2020-08-18 NZ NZ781143A patent/NZ781143A/en unknown
- 2020-08-18 CN CN202080055377.0A patent/CN114206914A/en active Pending
- 2020-08-18 US US16/996,042 patent/US11098112B2/en active Active
- 2020-08-18 KR KR1020227002041A patent/KR102519236B1/en active IP Right Grant
- 2020-08-18 US US16/996,007 patent/US11053280B2/en active Active
- 2020-08-18 SG SG11202110958QA patent/SG11202110958QA/en unknown
- 2020-08-18 KR KR1020237010909A patent/KR20230051296A/en active Search and Examination
- 2020-08-18 BR BR112021025438A patent/BR112021025438A2/en active Search and Examination
- 2020-08-18 SG SG11202110968VA patent/SG11202110968VA/en unknown
- 2020-08-18 EP EP20765402.1A patent/EP3906303A1/en active Pending
- 2020-08-18 KR KR1020237044978A patent/KR20240005222A/en active Application Filing
- 2020-08-18 KR KR1020237036668A patent/KR20230152810A/en active Application Filing
- 2020-08-18 CA CA3129193A patent/CA3129193C/en active Active
- 2020-08-18 IL IL296512A patent/IL296512B2/en unknown
- 2020-08-18 MY MYPI2021006223A patent/MY190623A/en unknown
- 2020-08-18 CA CA3172631A patent/CA3172631C/en active Active
- 2020-08-18 BR BR112021025359A patent/BR112021025359A2/en unknown
- 2020-08-18 IL IL296893A patent/IL296893B2/en unknown
- 2020-08-18 MY MYPI2022002100A patent/MY193355A/en unknown
- 2020-08-18 MY MYPI2022002113A patent/MY193353A/en unknown
- 2020-08-18 IL IL301888A patent/IL301888A/en unknown
- 2020-08-18 NZ NZ781137A patent/NZ781137A/en unknown
- 2020-08-18 TW TW109128143A patent/TW202122417A/en unknown
- 2020-08-18 AU AU2020397865A patent/AU2020397865C1/en active Active
- 2020-08-18 JP JP2022506127A patent/JP2022547652A/en active Pending
- 2020-08-18 CN CN202080055352.0A patent/CN114206907A/en active Pending
- 2020-08-18 MY MYPI2022002103A patent/MY193354A/en unknown
- 2020-08-18 IL IL296863A patent/IL296863B2/en unknown
- 2020-08-18 MY MYPI2022002109A patent/MY193350A/en unknown
- 2020-08-18 WO PCT/US2020/046809 patent/WO2021112923A1/en active Application Filing
- 2020-08-18 IL IL309491A patent/IL309491A/en unknown
- 2020-08-18 KR KR1020227002042A patent/KR20220035393A/en active Application Filing
- 2020-08-18 JP JP2022506072A patent/JP2022547651A/en active Pending
- 2020-08-18 NZ NZ781138A patent/NZ781138A/en unknown
- 2020-08-18 JP JP2022506130A patent/JP2022552052A/en active Pending
- 2020-08-18 TW TW109128139A patent/TW202128743A/en unknown
- 2020-08-18 NZ NZ781142A patent/NZ781142A/en unknown
- 2020-08-18 TW TW109128142A patent/TW202134256A/en unknown
- 2020-08-18 KR KR1020227002038A patent/KR102619866B1/en active IP Right Grant
- 2020-08-18 WO PCT/US2020/046842 patent/WO2021112927A1/en active Application Filing
- 2020-08-18 MX MX2022006788A patent/MX2022006788A/en unknown
- 2020-08-18 IL IL288367A patent/IL288367B2/en unknown
- 2020-08-18 IL IL288355A patent/IL288355B2/en unknown
- 2020-08-18 MY MYPI2021006201A patent/MY190625A/en unknown
- 2020-08-18 WO PCT/US2020/046823 patent/WO2021112924A1/en active Application Filing
- 2020-08-18 CA CA3159586A patent/CA3159586A1/en active Pending
- 2020-08-18 KR KR1020227002043A patent/KR20220038349A/en not_active IP Right Cessation
- 2020-08-18 CA CA3172625A patent/CA3172625A1/en active Pending
- 2020-08-18 AU AU2020397803A patent/AU2020397803C1/en active Active
- 2020-08-18 MX MX2022006758A patent/MX2022006758A/en unknown
- 2020-08-18 IL IL302921A patent/IL302921A/en unknown
- 2020-08-18 MX MX2022006760A patent/MX2022006760A/en unknown
- 2020-08-18 EP EP20765400.5A patent/EP3906250A1/en active Pending
- 2020-08-18 MY MYPI2021006189A patent/MY190624A/en unknown
- 2020-08-18 IL IL288352A patent/IL288352B2/en unknown
- 2020-08-18 WO PCT/US2020/046831 patent/WO2021112925A1/en active Application Filing
- 2020-08-18 PE PE2022001022A patent/PE20221788A1/en unknown
- 2020-08-18 TW TW109128145A patent/TW202128745A/en unknown
- 2020-08-18 CN CN202080055393.XA patent/CN114206924A/en active Pending
- 2020-08-18 IL IL309560A patent/IL309560A/en unknown
- 2020-08-18 BR BR112021025158A patent/BR112021025158A2/en not_active Application Discontinuation
- 2020-08-18 US US16/996,127 patent/US11180540B2/en active Active
- 2020-08-18 AU AU2020398547A patent/AU2020398547C1/en active Active
- 2020-08-18 WO PCT/US2020/046846 patent/WO2021112928A1/en active Application Filing
- 2020-08-18 MX MX2021014863A patent/MX2021014863A/en unknown
- 2020-08-18 US US16/996,103 patent/US11098311B2/en active Active
- 2020-08-18 KR KR1020227002039A patent/KR102519234B1/en active IP Right Grant
- 2020-08-18 KR KR1020237044758A patent/KR20240005206A/en active Application Filing
- 2020-08-18 SG SG11202110964QA patent/SG11202110964QA/en unknown
- 2020-08-18 EP EP20765403.9A patent/EP3931303A1/en active Pending
- 2020-08-18 PE PE2022001024A patent/PE20221261A1/en unknown
- 2020-08-18 KR KR1020237044969A patent/KR20240007293A/en active Application Filing
- 2020-08-18 JP JP2022506131A patent/JP2022548818A/en active Pending
- 2020-08-18 NZ NZ781145A patent/NZ781145A/en unknown
- 2020-08-18 TW TW109128144A patent/TW202128991A/en unknown
- 2020-08-18 AU AU2020396490A patent/AU2020396490C1/en active Active
- 2020-08-18 JP JP2022506067A patent/JP2022550930A/en active Pending
- 2020-08-18 MX MX2021014862A patent/MX2021014862A/en unknown
- 2020-08-18 JP JP2022506125A patent/JP2022548197A/en active Pending
- 2020-08-18 EP EP20775971.3A patent/EP3931204A1/en active Pending
- 2020-08-18 AU AU2020398830A patent/AU2020398830C1/en active Active
- 2020-08-18 IL IL296864A patent/IL296864B2/en unknown
- 2020-08-18 MX MX2022006759A patent/MX2022006759A/en unknown
- 2020-08-18 MY MYPI2022002104A patent/MY193351A/en unknown
- 2020-08-18 TW TW109128140A patent/TW202128744A/en unknown
- 2020-08-18 BR BR112022001016A patent/BR112022001016A2/en unknown
- 2020-08-18 PE PE2022001026A patent/PE20221791A1/en unknown
- 2020-08-18 PE PE2022001025A patent/PE20221790A1/en unknown
-
2021
- 2021-03-18 US US17/205,745 patent/US11174283B2/en active Active
- 2021-03-24 US US17/211,333 patent/US11286290B2/en active Active
- 2021-07-16 US US17/378,362 patent/US11440950B2/en active Active
- 2021-07-22 US US17/383,322 patent/US11535663B2/en active Active
- 2021-08-26 US US17/458,519 patent/US12054532B2/en active Active
- 2021-08-30 US US17/460,578 patent/US11306135B2/en active Active
- 2021-09-29 US US17/489,495 patent/US11299532B2/en active Active
- 2021-10-01 US US17/492,440 patent/US11407813B2/en active Active
- 2021-10-11 ZA ZA2021/07646A patent/ZA202107646B/en unknown
- 2021-10-11 ZA ZA2021/07647A patent/ZA202107647B/en unknown
- 2021-10-11 ZA ZA2021/07644A patent/ZA202107644B/en unknown
- 2021-10-13 US US17/500,735 patent/US11459373B2/en active Active
- 2021-12-02 MX MX2023005421A patent/MX2023005421A/en unknown
- 2021-12-02 MX MX2022011973A patent/MX2022011973A/en unknown
- 2021-12-02 MX MX2022012042A patent/MX2022012042A/en unknown
- 2021-12-21 US US17/557,904 patent/US11472861B2/en active Active
- 2021-12-30 CO CONC2021/0018214A patent/CO2021018214A2/en unknown
- 2021-12-30 CO CONC2021/0018181A patent/CO2021018181A2/en unknown
- 2021-12-30 CO CONC2021/0018234A patent/CO2021018234A2/en unknown
- 2021-12-30 CO CONC2021/0018203A patent/CO2021018203A2/en unknown
- 2021-12-30 CO CONC2021/0018192A patent/CO2021018192A2/en unknown
-
2022
- 2022-01-13 US US17/575,585 patent/US11649273B2/en active Active
- 2022-01-13 US US17/575,425 patent/US11485770B2/en active Active
- 2022-01-25 CO CONC2022/0000660A patent/CO2022000660A2/en unknown
- 2022-02-08 US US17/667,298 patent/US11505593B2/en active Active
- 2022-02-08 US US17/667,330 patent/US11459374B2/en active Active
- 2022-04-01 US US17/711,723 patent/US11505594B2/en active Active
- 2022-06-03 MX MX2023014077A patent/MX2023014077A/en unknown
- 2022-06-15 US US17/841,349 patent/US11548932B2/en active Active
- 2022-06-16 US US17/842,286 patent/US11542317B1/en active Active
- 2022-07-06 US US17/858,629 patent/US12054533B2/en active Active
- 2022-07-06 US US17/858,724 patent/US11753459B2/en active Active
- 2022-11-25 US US17/994,223 patent/US11732025B2/en active Active
-
2023
- 2023-03-01 US US18/116,166 patent/US12012444B2/en active Active
- 2023-03-07 US US18/118,558 patent/US12077570B2/en active Active
- 2023-03-14 AU AU2023201586A patent/AU2023201586A1/en active Pending
- 2023-03-14 AU AU2023201589A patent/AU2023201589A1/en active Pending
- 2023-03-14 AU AU2023201585A patent/AU2023201585A1/en active Pending
- 2023-03-14 AU AU2023201588A patent/AU2023201588A1/en active Pending
- 2023-03-14 AU AU2023201590A patent/AU2023201590A1/en active Pending
- 2023-03-21 AU AU2023201748A patent/AU2023201748A1/en active Pending
- 2023-06-23 US US18/340,707 patent/US12049489B2/en active Active
- 2023-06-23 US US18/213,779 patent/US11958894B2/en active Active
- 2023-06-26 US US18/214,282 patent/US12012445B2/en active Active
- 2023-07-11 IL IL304390A patent/IL304390A/en unknown
- 2023-09-08 JP JP2023145749A patent/JP2023171771A/en active Pending
- 2023-09-22 JP JP2023156642A patent/JP2023179531A/en active Pending
- 2023-10-12 JP JP2023176817A patent/JP2024009949A/en active Pending
- 2023-10-12 JP JP2023176837A patent/JP2024009950A/en active Pending
- 2023-11-20 JP JP2023196342A patent/JP2024026116A/en active Pending
-
2024
- 2024-04-16 US US18/637,124 patent/US20240309064A1/en active Pending
- 2024-04-17 US US18/638,362 patent/US20240294606A1/en active Pending
- 2024-06-12 JP JP2024094985A patent/JP2024119936A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL304390A (en) | Anti-vegf protein compositions and methods for producing the same | |
EP3451856A4 (en) | Methods for the production and use of myceliated high protein food compositions | |
EP3802812A4 (en) | Rna-targeting fusion protein compositions and methods for use | |
EP3824096A4 (en) | Novel antibodies and methods for making and using the same | |
EP3773718A4 (en) | Compositions and methods comprising anti-nrp2 antibodies | |
IL277797A (en) | Methods for making stable protein compositions | |
EP4037711A4 (en) | Compositions and methods comprising anti-nrp2 antibodies | |
GB202017593D0 (en) | Compositions and methods and uses relating thereto | |
IL286587A (en) | D-metyrosine compositions and methods for preparing same | |
EP3980037A4 (en) | Cardiomyocytes and compositions and methods for producing the same | |
IL290331A (en) | Rna-targeting ligands, compositions thereof, and methods of making and using the same | |
IL285489A (en) | Producing compositions comprising two or more antibodies | |
EP3927372A4 (en) | Optimized vaccine compositions and methods for making the same | |
EP3858851A4 (en) | Protein composition production method | |
GB2586313B (en) | Compositions and methods and uses relating thereto | |
AU2021401316A1 (en) | Protein compositions and methods for producing and using the same | |
EP3638693A4 (en) | Immunoglobulin compositions and process for obtaining the same |